Reports Q4 revenue $872.71M, consensus $856.86M. “We delivered excellent results in the fourth quarter, led by double-digit growth in Pharma, while instruments and recurring revenue both grew high single-digits in constant currency,” said Dr. Udit Batra, President and CEO, Waters (WAT) Corporation. “Growth accelerated across all regions, driven by strong adoption of new products and the success of our strategic initiatives.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT:
- Trump Trade: President to impose 25% tariffs on steel, aluminum imports
- Waters upgraded to Equal Weight from Underweight at Barclays
- WAT Earnings this Week: How Will it Perform?
- U.S. places new export controls on biotech equipment, Reuters reports
- Waters Showcases Growth Strategy at Healthcare Conference